Some GLP1RAs (liraglutide and semaglutide) have proved to have positive effects on cardiovascular outcomes in T2DM
Rather than acting through a single receptor or signalling pathway, published research suggests that GHK-Cu can influence numerous genes involved in tissue remodelling, inflammatory responses, antioxidant defence and cellular repair
Growing research indicates they can be used to help treat many other conditions as well, including addiction, Parkinsons and kidney disease
While the active pharmaceutical ingredients may be the same, compounded products have not undergone FDA review for safety, efficacy, or quality as finished formulations
Whalen on "The #1 GLP-1 Doctor: What Works, What Doesnt & Whats Next" on The Tamsen Show
Yes, you can switch from semaglutide to tirzepatide if you and your healthcare provider decide that tirzepatide would be a better option for you